Antidepressants and the risk of hyponatremia: A multi‐institutional cohort study using observational medical outcomes partnership—Common Data Model
Authors:
- Kyungyeon JungKJKyungyeon Jung
- Ju Hwan KimJKJu Hwan Kim
- Da Eun HyeonDHDa Eun Hyeon
- Jeongmoon JiJJJeongmoon Ji
- Min Young LeeMLMin Young Lee
- Hayun ChoiHCHayun Choi
- Dong Yun LeeDLDong Yun Lee
- Min Woo KimMKMin Woo Kim
- Yoonmin JangYJYoonmin Jang
- Seonghoon HwangSHSeonghoon Hwang
- Jaehyeong ChoJCJaehyeong Cho
- Seok Young SongSSSeok Young Song
Open Access
- 13 January 2026
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (6) , 1706-1715
Abstract
Aim: Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods: Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023), we identified patients diagnosed with depression who initiated antidepressants, including selective serotonin reuptake inhibitor (SSRI), serotonin–norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressants (TCA) or others (agomelatine, bupropion, mirtazapine, moclobemide and trazodone) for at least 30 days. The index date was defined as the first antidepressant prescription, and four mutually exclusive cohorts were constructed based on the antidepressant class prescribed on index date. Each cohort was compared with all other antidepressants. The primary outcome was incident hyponatremia (serum sodium <135 mmol/L) within the first 180 days. After propensity score stratification, hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression. Fixed‐effect meta‐analysis was used to pool the results from each site. Results: We identified 17 895 (42.6%) patients in SSRI, 7395 (17.6%) in SNRI, 5424 (12.9%) in TCA and 11 322 (26.9%) in other group. The risk of hyponatremia increased within 180 days after SSRI initiation (HR 1.18, 95% CI 1.01–1.38) compared with all other depressants, with a higher risk in patients aged ≥60 years (1.29, 1.06–1.57). No significant association was found for SNRIs (1.05, 0.87–1.27), TCAs (1.03, 0.84–1.26) or other (0.90, 0.77–1.06). Conclusion: Close monitoring of serum sodium levels is essential for SSRI users, especially those aged ≥60 years.Keywords
This publication has 37 references indexed in Scilit:
- THE RISK OF ANTIDEPRESSANT-INDUCED HYPONATREMIA: A META- ANALYSIS OF ANTIDEPRESSANT CLASSES AND COMPOUNDSInternational Journal of Neuropsychopharmacology, 2025
- Hyponatremia Associated with the Use of Common Antidepressants in the All of Us Research ProgramClinical Pharmacology & Therapeutics, 2024
- Hyponatraemia—treatment standard 2024Nephrology Dialysis Transplantation, 2024
- Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic StudiesClinical Pharmacology & Therapeutics, 2022
- Antidepressants and HyponatremiaThe American Journal of Medicine, 2018
- Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older AdultsAmerican Journal of Kidney Diseases, 2017
- Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysisCochrane Database of Systematic Reviews, 2016
- Antidepressants and the Risk of Hyponatremia: A Class-by-Class Review of LiteraturePsychosomatics, 2014
- Age-Associated Abnormalities of Water HomeostasisEndocrinology and Metabolism Clinics of North America, 2013
- Significance of hypo- and hypernatremia in chronic kidney diseaseNephrology Dialysis Transplantation, 2012